| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| AVTX | AVTX | Shares | USD | XNCM |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| AVTX | AVTX | Shares | USD | XNCM |
Avalo Therapeutics, Inc. develops therapies for immune-mediated inflammatory diseases by targeting the IL-1β pathway, which plays a key role in inflammation. Its lead product, abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody being investigated for hidradenitis suppurativa and other immune-mediated conditions. The company is also advancing AVTX-010, a long-acting anti-IL-1β monoclonal antibody designed to extend dosing intervals. Avalo focuses on addressing significant unmet clinical needs in various global markets.
No recent RNS announcements for AVTX across AVTX.
No recent RNS announcements for AVTX across AVTX.